As of 2025-03-21, the Relative Valuation of Kiniksa Pharmaceuticals Ltd (KNSA) is (16.43) USD. This relative valuation is based on P/E multiples. With the latest stock price at 23.81 USD, the upside of Kiniksa Pharmaceuticals Ltd based on Relative Valuation is -169.0%.
The range of the Relative Valuation is (14.72) - (17.34) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 24.8x - 37.1x | 31.0x |
| Forward P/E multiples | 19.4x - 29.2x | 24.3x |
| Fair Price | (14.72) - (17.34) | (16.43) |
| Upside | -161.8% - -172.8% | -169.0% |
| Date | P/E |
| 2025-03-18 | -38.02 |
| 2025-03-17 | -38.63 |
| 2025-03-14 | -38.02 |
| 2025-03-13 | -37.27 |
| 2025-03-12 | -37.84 |
| 2025-03-11 | -36.24 |
| 2025-03-10 | -35.08 |
| 2025-03-07 | -36.17 |
| 2025-03-06 | -35.77 |
| 2025-03-05 | -35.97 |
| 2025-03-04 | -35.87 |
| 2025-03-03 | -36.09 |
| 2025-02-28 | -34.11 |
| 2025-02-27 | -33.01 |
| 2025-02-26 | -33.11 |
| 2025-02-25 | -33.16 |
| 2025-02-24 | -33.01 |
| 2025-02-21 | -33.67 |
| 2025-02-20 | -33.11 |
| 2025-02-19 | -33.16 |
| 2025-02-18 | -32.88 |
| 2025-02-14 | -33.20 |
| 2025-02-13 | -33.05 |
| 2025-02-12 | -32.42 |
| 2025-02-11 | -33.13 |
| 2025-02-10 | -32.96 |
| 2025-02-07 | -32.78 |
| 2025-02-06 | -34.12 |
| 2025-02-05 | -33.01 |
| 2025-02-04 | -31.52 |
| 2025-02-03 | -31.75 |
| 2025-01-31 | -32.96 |
| 2025-01-30 | -33.43 |
| 2025-01-29 | -34.75 |
| 2025-01-28 | -33.94 |
| 2025-01-27 | -34.91 |
| 2025-01-24 | -33.69 |
| 2025-01-23 | -33.25 |
| 2025-01-22 | -32.31 |
| 2025-01-21 | -31.47 |
| 2025-01-17 | -31.18 |
| 2025-01-16 | -30.93 |
| 2025-01-15 | -31.65 |
| 2025-01-14 | -30.84 |
| 2025-01-13 | -30.56 |
| 2025-01-10 | -33.52 |
| 2025-01-08 | -34.14 |
| 2025-01-07 | -33.64 |
| 2025-01-06 | -33.67 |
| 2025-01-03 | -34.16 |